303 related articles for article (PubMed ID: 10776081)
1. Intravenous iron products.
Johnson CA; Mason NA; Bailie GR
ANNA J; 1999 Oct; 26(5):522-4. PubMed ID: 10776081
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of sodium ferric gluconate complex in iron-deficient pediatric hemodialysis patients.
Kaskel FJ
Nat Clin Pract Nephrol; 2006 May; 2(5):244-5. PubMed ID: 16932433
[No Abstract] [Full Text] [Related]
3. Effectiveness of oral and intravenous iron therapy in haemodialysis patients.
Jenq CC; Tian YC; Wu HH; Hsu PY; Huang JY; Chen YC; Fang JT; Yang CW
Int J Clin Pract; 2008 Mar; 62(3):416-22. PubMed ID: 17511797
[TBL] [Abstract][Full Text] [Related]
4. Safe administration of iron sucrose in a patient with a previous hypersensitivity reaction to ferric gluconate.
Sane R; Baribeault D; Rosenberg CL
Pharmacotherapy; 2007 Apr; 27(4):613-5. PubMed ID: 17381390
[TBL] [Abstract][Full Text] [Related]
5. Acute injury with intravenous iron and concerns regarding long-term safety.
Bishu K; Agarwal R
Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S19-23. PubMed ID: 17699372
[TBL] [Abstract][Full Text] [Related]
6. Review of available intravenous iron preparations in hemodialysis.
Palmer K; Cameron K; Battistella M
CANNT J; 2013; 23(2):51-4; quiz 55-6. PubMed ID: 24069699
[No Abstract] [Full Text] [Related]
7. Oral or intravenous iron for anemia correction in chronic kidney disease?
Drüeke TB; Massy ZA
Kidney Int; 2015 Oct; 88(4):673-5. PubMed ID: 26422625
[TBL] [Abstract][Full Text] [Related]
8. IV iron use in patients with higher serum ferritin: case study on anemia in kidney disease.
Larson K
Nephrol Nurs J; 2008; 35(2):184-93; quiz 194-5. PubMed ID: 18472686
[TBL] [Abstract][Full Text] [Related]
9. Parenteral iron use in the management of anemia in end-stage renal disease patients.
Bailie GR; Johnson CA; Mason NA
Am J Kidney Dis; 2000 Jan; 35(1):1-12. PubMed ID: 10620537
[TBL] [Abstract][Full Text] [Related]
10. Use of intravenous iron supplementation in chronic kidney disease: an update.
Macdougall IC; Geisser P
Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial.
Van Wyck DB; Cavallo G; Spinowitz BS; Adhikarla R; Gagnon S; Charytan C; Levin N
Am J Kidney Dis; 2000 Jul; 36(1):88-97. PubMed ID: 10873877
[TBL] [Abstract][Full Text] [Related]
12. Intravenous iron sucrose versus oral iron ferrous sulfate for antenatal and postpartum iron deficiency anemia: a randomized trial.
Froessler B; Cocchiaro C; Saadat-Gilani K; Hodyl N; Dekker G
J Matern Fetal Neonatal Med; 2013 May; 26(7):654-9. PubMed ID: 23130909
[TBL] [Abstract][Full Text] [Related]
13. Letter to the editor: treatment of iron deficiency anemia.
Ozsoylu S
Pediatr Hematol Oncol; 2005; 22(7):645-6; author reply 647-8. PubMed ID: 16166057
[No Abstract] [Full Text] [Related]
14. A randomized trial of intravenous and oral iron in chronic kidney disease.
Agarwal R; Kusek JW; Pappas MK
Kidney Int; 2015 Oct; 88(4):905-14. PubMed ID: 26083656
[TBL] [Abstract][Full Text] [Related]
15. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis.
Silverberg DS; Iaina A; Peer G; Kaplan E; Levi BA; Frank N; Steinbruch S; Blum M
Am J Kidney Dis; 1996 Feb; 27(2):234-8. PubMed ID: 8659499
[TBL] [Abstract][Full Text] [Related]
16. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans.
Faich G; Strobos J
Am J Kidney Dis; 1999 Mar; 33(3):464-70. PubMed ID: 10070910
[TBL] [Abstract][Full Text] [Related]
17. Targeting Iron Deficiency Anemia in Heart Failure.
Saraon T; Katz SD
Prog Cardiovasc Dis; 2016; 58(4):407-15. PubMed ID: 26657161
[TBL] [Abstract][Full Text] [Related]
18. Addressing patient concerns about intravenous iron therapy.
Robbins KC
Nephrol Nurs J; 2003 Apr; 30(2):220-4, 258. PubMed ID: 12737000
[TBL] [Abstract][Full Text] [Related]
19. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
[TBL] [Abstract][Full Text] [Related]
20. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]